Romazicon

• Aquaresis promoters

• Anexate
• Flumazenil [USAN:BAN:INN]
• Flumazenilo [Spanish]
• Flumazenilum [Latin]
• Flumazepil
• Lanexat
• Mazicon
• Romazicon

• No information avaliable

C₃₂H₂₆N₄O₂

No information avaliable

Romazicon FDA

No information avaliable

498.575 g/mol

No information avaliable

Very slightly soluble (0.15 mg/mL at 23oC)

Solid

5.955

Liquid (ampule containing 20 mg conivaptan hydrochloride)

For the treatment of euvolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.

Conivaptan is a nonpeptide, dual antagonist of arginine vasopressin (AVP) V_1A and V₂ receptors. The level of AVP in circulating blood is critical for the regulation of water and electrolyte balance and is usually elevated in both euvolemic and hypervolemic hyponatremia. The AVP effect is mediated through V₂ receptors, which are functionally coupled to aquaporin channels in the apical membrane of the collecting ducts of the kidney. These receptors help to maintain plasma osmolality within the normal range. The predominant pharmacodynamic effect of conivaptan in the treatment of hyponatremia is through its V₂ antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water. The pharmacodynamic effects of conivaptan include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.

No information avaliable

Although no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.

No information avaliable

Humans and other mammals